Home
About
About Anagenics
Directors and Management
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease
Home
Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease
Published by
Tiffany McMillan
on
November 14, 2019
Categories
Tags
Share
0
Tiffany McMillan
